Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | WNT3 | P56703 | 2/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556375 | 0.86 | MEN1 (0.55) | MEN1KMT2ANPC1RXFP1BUB1 | |
| SCHEMBL30463745 | 0.86 | MEN1 (0.55) | MEN1KMT2ANPC1RXFP1BUB1 | |
| SCHEMBL18335882 | 0.73 | NPC1 (0.54) | MEN1KMT2ANPC1BUB1LMNA | |
| SCHEMBL18335884 | 0.73 | NPC1 (0.54) | MEN1KMT2ANPC1BUB1LMNA | |
| SCHEMBL23701612 | 0.73 | RXFP1 (0.50) | MEN1KMT2ARXFP1TRPV1 | |
| SCHEMBL30463796 | 0.72 | KMT2A (0.51) | KMT2ARXFP1MAPTTACR1TGFBR1 | |
| SCHEMBL10132534 | 0.71 | NPC1 (0.56) | MEN1KMT2ANPC1MAPTLMNA | |
| SCHEMBL28631554 | 0.71 | ALDH1A1 (0.53) | MEN1KMT2ANPC1MAPTLMNA | |
| SCHEMBL22571395 | 0.71 | RXFP1 (0.51) | RXFP1LMNA | |
| SCHEMBL30463793 | 0.71 | RXFP1 (0.51) | RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | MEN1 3793/4885KMT2A 2329/4885NPC1 2236/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | MEN1 3793/4885KMT2A 2329/4885NPC1 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.